Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.

[thumbnail of Oncology Fact Sheet Nr.65.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
103kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 700-875 Male genitalia
Language:	English
Series Name:	Oncology Fact Sheet Nr. 65
Deposited on:	28 Jul 2022 12:59
Last Modified:	28 Jul 2022 12:59

Repository Staff Only: item control page